Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Citi downgraded both AbbVie (NYSE:ABBV) and Merck (NSE:PROR) to Neutral in separate notes Wednesday, citing long-term growth ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Pharma giant Merck & Co. (MRK) just got an 8% boost after competitor data fell short of investor expectations. Last week, investors were underwhelmed when Chinese data revealed that the ivonescimab ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...